Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2017

01-12-2017 | Research Article

Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2

Authors: Noeen Malik, Andrew N Gifford, Johan Sandell, Daniel Tuchman, Yu-Shin Ding

Published in: Molecular Imaging and Biology | Issue 6/2017

Login to get access

Abstract

Purpose

LRRK2 (leucine-rich repeat kinase 2) has recently been proven to be a promising drug target for Parkinson’s disease (PD) due to an apparent enhanced activity caused by mutations associated with familial PD. To date, there have been no reports in which a LRRK2 inhibitor has been radiolabeled and used for in in vitro or in vivo studies of LRRK2. In the present study, we radiolabeled the LRRK2 ligand, LRRK-IN-1, for the purposes of performing in vitro (IC50, K d , B max, autoradiography) and in vivo (biodistribution, and blocking experiments) evaluations in rodents and human striatum tissues.

Procedures

[3H]LRRK2-IN-1 was prepared with high radiochemical purity (>99 %) and a specific activity of 41 Ci/mmol via tritium/hydrogen (T/H) exchange using Crabtree’s catalyst. For IC50, K d , and B max determination, LRRK2-IN-1 was used as a competing drug for nonspecific binding assessment. The specific binding of the tracer was further evaluated via an in vivo blocking study in mice with a potent LRRK2 inhibitor, Pf-06447475.

Results

In vitro binding studies demonstrated a saturable binding site for [3H]LRRK2-IN-1 in rat kidney, rat brain striatum and human brain striatum with K d of 26 ± 3 and 43 ± 8, 48 ± 2 nM, respectively. In rat, the density of LRRK2 binding sites (B max) was higher in kidney (6.4 ± 0.04 pmol/mg) than in brain (2.5 ± 0.03 pmol/mg), however, in human brain striatum, the B max was 0.73 ± 0.01 pmol/mg protein. Autoradiography imaging in striatum of rat and human brain tissues gave results consistent with binding studies. In in vivo biodistribution and blocking studies in mice, co-administration with Pf-06447475 (10 mg/kg) reduced the uptake of [3H]LRRK2-IN-1 (%ID/g) by 50–60% in the kidney or brain.

Conclusion

The high LRRK2 brain density observed in our study suggests the feasibility for positron emission tomography imaging of LRRK2 (a potential target) with radioligands of higher affinity and specificity.
Literature
1.
Bosgraaf L, van Haastert PJ (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5–10CrossRefPubMed
2.
3.
West AB, Moore DJ, Biskup S et al (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842–16847CrossRefPubMedPubMedCentral
4.
Smith WW, Pei Z, Jiang H et al (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231–1233CrossRefPubMed
5.
Bonifati V (2006) The LRRK2-G2019S mutation: opening a novel era in Parkinson’s disease genetics. Eur J Hum Genet 14:1061–1062CrossRefPubMed
6.
Luzón-Toro B, Rubio de la Torre E, Delgado A (2007) Mechanistic insight into the dominant mode of the Parkinson’s disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16:2031–2039CrossRefPubMed
7.
Jaleel M, Nichols RJ, Deak M et al (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem J 405:307–317CrossRefPubMedPubMedCentral
8.
Anand VS, Reichling LJ, Lipinski K et al (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 276:466–478CrossRefPubMed
9.
Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:595–600CrossRefPubMed
10.
Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607CrossRefPubMed
11.
Adams JR, van Netten H, Schulzer M et al (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128(Pt 12):2777–2785CrossRefPubMed
12.
Guo L, Gandhi PN, Wang W et al (2007) The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:3658–3670CrossRefPubMedPubMedCentral
13.
14.
15.
Daechsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67:542–547
16.
17.
18.
Berger Z, Smith KA, LaVoie MJ (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemist 49:5511–5523CrossRef
19.
Nichols RJ, Dzamko N, Morrice NA et al (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430:393–404CrossRefPubMedPubMedCentral
20.
Civiero L, Vancraenenbroeck R, Belluzzi E et al (2012) Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One 7:e43472CrossRefPubMedPubMedCentral
21.
22.
Bahnassawy L, Nicklas S, Palm T et al (2013) The Parkinson’s disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells. Stem Cells Dev 22:2487–2496CrossRefPubMed
23.
Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39CrossRefPubMed
24.
Deng X, Dzamko N, Prescott A et al (2011) Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol 7:203–205CrossRefPubMedPubMedCentral
25.
Reith AD, Bamborough P, Jandu K et al (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22:5625–5629CrossRefPubMedPubMedCentral
26.
Estrada AA, Liu X, Baker-Glenn C et al (2012) Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 55:9416–9433CrossRefPubMed
27.
Kavanagh ME, Doddareddy MR, Kassiou M (2013) The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorg Med Chem Lett 23:3690–3696CrossRefPubMed
28.
Davies P, Hinkle KM, Sukar NN et al (2013) Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem J 453:101–113CrossRefPubMedPubMedCentral
29.
Estrada AA, Chan BK, Baker-Glenn C et al (2014) Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 57:921–936CrossRefPubMed
30.
Henderson JL, Kormos BL, Hayward MM et al (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2, 3-d]pyrimidin-5-yl] benzonitrile (Pf-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 58:419–432CrossRefPubMed
31.
Daher JP, Abdelmotilib HA, Hu X et al (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration. J Biol Chem 290:19433–19444CrossRefPubMedPubMedCentral
32.
Koshibu K, van Asperen J, Gerets H et al (2015) Alternative to LRRK2-IN-1 for pharmacological studies of Parkinson’s disease. Pharmacology 96:240–247CrossRefPubMed
33.
Liu Z, Galemmo RA Jr, Fraser KB et al (2014) Unique functional and structural properties of the LRRK2 protein ATP-binding pocket. J Biol Chem 289:32937–32951CrossRefPubMedPubMedCentral
34.
Gray NS, Waller D, Choi HG et al (2014) Pyrimido-diazepinone compounds and methods of treating disorders. Patent: WO 2014145909:A3
35.
Dzamko N, Deak M, Hentati F et al (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430:405–413CrossRefPubMedPubMedCentral
36.
Taylor SS, Kornev AP (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36:65–77CrossRefPubMed
37.
38.
West AB, Cowell RM, Daher JP et al (2014) Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol 522:2465–2480CrossRefPubMedPubMedCentral
39.
Dorval V, Mandemakers W, Jolivette F et al (2014) Gene and MicroRNA transcriptome analysis of Parkinson’s related LRRK2 mouse models. PLoS One 9:e85510CrossRefPubMedPubMedCentral
40.
Maekawa T, Kubo M, Yokoyama I et al (2010) Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochem Biophys Res Commun 392:431–435CrossRefPubMed
41.
Taymans JM, Van den Haute C, Baekelandt V (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98:951–961CrossRefPubMed
42.
Miklossy J, Arai T, Guo JP et al (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 65:953–963CrossRefPubMed
43.
Westerlund M, Belin AC, Anvret A et al (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson’s disease. Neuroscience 152:429–436CrossRefPubMed
44.
Herzig MC, Kolly C, Persohn E et al (2010) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209–4223CrossRef
45.
Baptista MA, Dave KD, Frasier MA et al (2012) Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One 8:e80705CrossRef
46.
Tong Y, Giaime E, Yamaguchi H et al (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7:2CrossRefPubMedPubMedCentral
47.
Fell MJ, Mirescu C, Basu K et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355:397–409CrossRefPubMed
48.
49.
Hall H, Sedvall G, Magnusson O et al (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacol 11:245–256CrossRef
50.
Quirion R, Pilapil C, Allaoua H et al (1995) Autoradiographic distribution of multiple opioid, sigma and phencyclidine receptor binding sites in the human brain. In: Biegon A, Volkow ND (eds) ISBN: 084937653XSites of drug action in the human brain, pp 117–141
51.
Kulkarni AD, Patel HM, Surana SJ et al (2016) Brain-blood ratio: implications in brain drug delivery. Expert Opin Drug Deliv 13:85–92CrossRefPubMed
52.
Convents A, De Keyser J, De Backer JP et al (1989) [3H] rauwolscine labels alpha 2-adrenoceptors and 5-HT1A receptors in human cerebral cortex. Eur J Pharmacol 159(3):307–310CrossRefPubMed
53.
Durany N, Zoechling R, Boissl KW et al (2000) Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 287:109–112CrossRefPubMed
54.
Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140:1–22CrossRefPubMed
55.
56.
Hicks JW, VanBrocklin HF, Wilson AA et al (2010) Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. Molecules 15:8260–8278CrossRefPubMed
57.
Sun J, Cai L, Zhang K et al (2014) A pilot study on EGFR-targeted molecular imaging of PET/CT with 11C-PD153035 in human gliomas. Clin Nucl Med 39:e20–e26CrossRefPubMed
Metadata
Title
Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2
Authors
Noeen Malik
Andrew N Gifford
Johan Sandell
Daniel Tuchman
Yu-Shin Ding
Publication date
01-12-2017
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 6/2017
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-017-1070-1

Other articles of this Issue 6/2017

Molecular Imaging and Biology 6/2017 Go to the issue

Research Article

Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation

Erratum

Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer

Research Article

Preliminary PET/CT Imaging with Somatostatin Analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC

Research Article

A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer

Research Article

In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats

Commentary

The Fermi Paradox in STEM—Where Are the Women Leaders?